Short Interest in Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Rises By 49.4%

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) saw a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 103,800 shares, an increase of 49.4% from the January 15th total of 69,500 shares. Approximately 15.2% of the company’s shares are short sold. Based on an average daily volume of 69,600 shares, the days-to-cover ratio is currently 1.5 days.

Qualigen Therapeutics Stock Performance

NASDAQ:QLGN opened at $3.71 on Friday. Qualigen Therapeutics has a 12-month low of $2.96 and a 12-month high of $29.43. The stock’s fifty day simple moving average is $3.93 and its 200-day simple moving average is $6.29.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.